• Antengene signed an exclusive, sublicensable global ex-China license with MPM BioImpact-backed K2 for ATG-106, a CDH6 x CD3 T-cell engager.
• Rights cover research, development, manufacturing, commercialization worldwide, excluding Mainland China, Hong Kong, Macau, Taiwan.
• Deal includes about USD 20 million upfront and near-term consideration, split between cash and a minority equity stake, subject to conditions.
• Milestones for ATG-106 total up to USD 960.5 million.
• K2 also received an exclusive option on an undisclosed preclinical bispecific TCE on similar economics, including up to USD 960.5 million milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260622-12209444), on June 22, 2026, and is solely responsible for the information contained therein.